Skip to main content
. 2021 Nov 10;7(46):eabi8178. doi: 10.1126/sciadv.abi8178

Fig. 5. Primary validation of incipient AD proteomic signature.

Fig. 5.

Results of primary validation analyses performed using Western blotting in 3xTg-AD transgenic mice (AD) compared to wild type (WT) (A) and human brain tissue samples comparing AD to CN (B). The 3xTg-AD (n = 6) and WT (n = 6) mice included young (38 to 40 weeks) and old (83 to 136 weeks) mice. (A) Box plots represent differences in protein levels in brain homogenates between 3xTg-AD (blue) and WT (red) mice. The top and bottom rows indicate protein levels in young and old mice, respectively. (B) Box plots represent differences in protein levels in brain homogenates between AD (blue; n = 11) and CN (red; n = 11). Protein levels that were significantly different between 3xTg-AD and WT or AD and CN are indicated with * (P < 0.05) or ** (P < 0.01). 3xTg-AD, 3xTg-AD transgenic mouse model of AD; AD, Alzheimer’s disease; WT, wild type; DUSP3, dual-specificity phosphate 3; STAT3, signal transducer and activator of transcription 3; TOP1, DNA topoisomerase I; FYN1, FYN proto-oncogene tyrosine kinase; LGALS8, galectin-8; YES1, YES proto-oncogene tyrosine kinase.